Form S-8 ARVINAS, INC.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Arvinas Inc. (ARVN) PT Lowered to $81 at H.C. Wainwright
February 12, 2025 6:44 AM ESTH.C. Wainwright analyst Andrew Fein lowered the price target on Arvinas Inc. (NASDAQ: ARVN) to $81.00 (from $87.00) while maintaining a Buy rating.
The analyst comments "VERITAC-2 trial design differences can impact mPFS outcome. As Arvinas plans to share the Phase 3 data from the vepdeg monotherapy trial in 1Q 2025, we remain encouraged that a CBR of 37.1% and 38.9% in 200 mg QD and 500 mg QD is impressive, and we consider it might result in a competitive mPFS in comparison to the EMERALD data of 3.8 months (elacestrant arm) versus 1.9 months (control).... More
